CVRx (CVRX) AI Stock Analysis

• Market Cap: $263.61M
• Dividend Yield: N/A
• Average Volume (3M): 202.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 23.11%
• EPS Growth: 18.06%
• Country: US
• Employees: 206
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.57
• Shares Outstanding: 26,151,724
• 10 Day Avg. Volume: 195,099
• 30 Day Avg. Volume: 202,291
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.41
• Enterprise Value/Revenue: 1.99
• Enterprise Value/Gross Profit: 2.37
• Enterprise Value/Ebitda: -2.36
• 1Y Price Target: $11.50
• Price Target Upside: 10.05% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 58 Neutral
• Price Target: $10.50 ▲(0.48% Upside)

CVRx's stock score is primarily influenced by its financial performance challenges, including negative profitability and cash flow issues. However, strong technical indicators and positive earnings call sentiment provide support. Valuation remains a concern due to the negative P/E ratio, but the company's growth initiatives and reimbursement improvements offer potential for future improvement.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and successful product adoption, enhancing long-term business sustainability.

Expansion of Implanting Centers

Expanding implanting centers strengthens market presence and accessibility, supporting future revenue growth and competitive positioning.

Reimbursement Improvements

Improved reimbursement strategies enhance financial predictability and incentivize healthcare providers, boosting product adoption.

Negative Factors

Profitability Challenges

Ongoing net losses highlight profitability challenges, which may hinder reinvestment capabilities and long-term financial health.

Rising SG&A Expenses

Increasing SG&A expenses can pressure margins and reduce operational efficiency, impacting overall profitability and cash flow.

Interest Expense Rise

Rising interest expenses due to increased borrowings can strain cash flow and limit financial flexibility, affecting long-term stability.

CVRx Business Overview & Revenue Model

Company Description

CVRx, Inc. is a medical device company focused on developing innovative therapies for patients with cardiovascular diseases. The company specializes in implantable technologies that target hypertension and heart failure, with its flagship product being the Barostim Therapy system. This system is designed to improve heart function and reduce blood pressure by stimulating the baroreceptors in the carotid artery. CVRx operates primarily in the healthcare sector, aiming to enhance patient outcomes through its advanced medical devices.

How the Company Makes Money

CVRx generates revenue primarily through the sale of its Barostim Therapy systems and related products, which are sold to hospitals and healthcare providers. The company has established key partnerships with medical institutions and health systems to promote the adoption of its technology. Additionally, CVRx benefits from reimbursements from healthcare payers for the procedures involving its devices, which is a significant revenue stream. The company may also engage in clinical studies and collaborations that can lead to new product developments, further enhancing its revenue potential.

CVRx Financial Statement Overview

Summary

CVRx shows revenue growth and a strong gross profit margin, but faces profitability challenges with negative net income and EBIT margins. The balance sheet is stable with a moderate debt-to-equity ratio, yet negative return on equity reflects ongoing financial struggles. Cash flow issues persist with negative operating and free cash flows, indicating potential liquidity concerns.

Income Statement

CVRx has shown consistent revenue growth, with a TTM revenue growth rate of 3.37%. However, the company is currently unprofitable, with negative net profit margins and EBIT margins, indicating challenges in achieving operational efficiency. The gross profit margin remains strong at 84%, suggesting effective cost management at the production level.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.87, indicating a balanced approach to leveraging. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is healthy, suggesting a solid capital structure despite the negative profitability.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a slight decline in free cash flow growth. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. However, the free cash flow to net income ratio is slightly above 1, indicating that free cash flow is closely aligned with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.65M	51.29M	39.30M	22.47M	13.04M	6.05M
Gross Profit	45.93M	42.96M	33.04M	17.47M	9.40M	4.61M
EBITDA	-46.15M	-54.89M	-38.73M	-40.74M	-40.60M	-11.48M
Net Income	-52.25M	-59.97M	-41.20M	-41.43M	-43.08M	-14.11M
Balance Sheet
Total Assets	119.56M	133.41M	115.23M	124.94M	152.55M	64.78M
Cash, Cash Equivalents and Short-Term Investments	95.03M	105.93M	90.57M	106.19M	142.07M	59.11M
Total Debt	50.54M	50.43M	30.61M	7.09M	0.00	19.28M
Total Liabilities	61.63M	62.36M	39.28M	15.76M	6.59M	358.01M
Stockholders Equity	57.93M	71.06M	75.95M	109.18M	145.96M	-293.24M
Cash Flow
Free Cash Flow	-39.43M	-40.51M	-39.61M	-43.36M	-28.91M	-16.41M
Operating Cash Flow	-39.12M	-39.14M	-39.02M	-42.68M	-27.73M	-16.10M
Investing Cash Flow	-306.00K	-1.36M	-591.00K	-685.00K	-1.18M	-311.00K
Financing Cash Flow	64.04M	55.87M	23.98M	7.49M	111.88M	49.78M

CVRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVRX, the sentiment is Positive. The current price of 10.45 is above the 20-day moving average (MA) of 9.16, above the 50-day MA of 8.17, and above the 200-day MA of 9.34, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 76.38 is Negative, neither overbought nor oversold. The STOCH value of 83.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVRX.

CVRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	71 Outperform	$268.40M	20.42	10.79%	―	17.11%	45.34%
ELMD	70 Outperform	$202.63M	28.63	17.18%	―	16.97%	48.56%
CVRX	58 Neutral	$263.61M	―	-92.33%	―	23.11%	18.06%
XTNT	57 Neutral	$112.14M	-22.44	-9.80%	―	15.16%	-39.18%
INGN	56 Neutral	$237.14M	―	-13.46%	―	5.15%	73.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NNOX	44 Neutral	$260.79M	―	-32.87%	―	17.36%	9.38%

CVRx Corporate Events

Cvrx, Inc. Earnings Call Highlights Growth and Challenges

The recent earnings call of Cvrx, Inc. painted a balanced picture of the company’s current financial health and future prospects. While the company reported significant revenue growth and operational expansion, these positive developments were tempered by increased net losses and rising expenses. Improvements in reimbursement and strategic advancements in clinical trials offer a positive outlook, though challenges in sales force productivity and increased expenses contribute to a cautious sentiment.

CVRx, Inc. Reports Strong Q2 2025 Growth

CVRx, Inc. is a commercial-stage medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, notably through its Barostim technology. In its second quarter of 2025, CVRx reported a revenue increase of 15% year-over-year, reaching $13.6 million. The U.S. heart failure segment contributed significantly to this growth, with revenue climbing to $12.1 million. The company also expanded its active implanting centers in the U.S. to 240, a 27% increase from the previous year, highlighting its strategic growth in new sales territories and increased awareness of Barostim.

CVRx Appoints Brent Binkowski as New COO

On August 4, 2025, CVRx announced the appointment of Brent Binkowski as Chief Operating Officer, effective August 11, 2025. Binkowski brings over 20 years of experience in medical devices, which is expected to enhance CVRx’s operations. The company reported a 15% increase in total revenue for the second quarter of 2025, reaching $13.6 million, driven by growth in the U.S. heart failure market. The number of active implanting centers in the U.S. grew by 27% since June 2024. CVRx is also benefiting from favorable CMS proposals for Barostim reimbursement, positioning the company for continued growth.

The most recent analyst rating on (CVRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.